Marginal zone lymphoma (MZL) is a rare, slow-growing cancer of the lymphatic system that develops from a type of blood cell called a B lymphocyte. There are three distinct types of MZL - mucosa-associated lymphoid tissue (MALT) lymphoma, nodal MZL, and splenic MZL. Although MZL cannot be cured, there are effective treatments available and some people can live with MZL for many years.
'Fast Facts: Marginal Zone Lymphoma' provides an overview of MZL for healthcare professionals and others with an interest in this blood cancer. It summarizes what is known about the pathophysiology of the disease, and discusses the importance of accurate diagnosis, staging, and prognosis, together with existing approaches to treatment and monitoring, including the latest evidence for new therapies in the R/R setting. With an eye to the future, it also reviews some of the therapies in development, which may ultimately improve quality of life and ensure better outcomes for patients with MZL.
'Fast Facts: Follicular Lymphoma' provides an introduction to follicular lymphoma for healthcare professionals and others with an interest in this blood cancer. It summarizes what is known about the pathophysiology of the disease, and discusses the importance of accurate diagnosis, classification, and risk assessment, together with existing approaches to treatment and monitoring. Looking into the future, it also reviews some of the therapies in development, which may ultimately improve quality of life and ensure better outcomes for patients with FL.
Lymphoma can be broadly defined as a cancer of mature lymphocytes. Our understanding of the biology of normal lymphocytes and lymphoma has grown at a tremendous pace, and this is now directly translating into changes in clinical practice. This became evident with the introduction of one of the first therapeutic monoclonal antibodies into cancer medicine, the CD20-directed antibody rituximab, which has led to significant benefit for patients with B-cell lymphomas. Since then, a raft of novel agents has entered clinical practice, including targeted small molecules, antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor (CAR) T cells. This new edition of 'Fast Facts: Lymphoma' has been updated to include recent changes in our understanding of lymphoma biology as well as improvements in diagnostics and therapeutics.
For nearly 25 years, Ferri's concise, pocket-sized resource has served as the go-to reference for practical, clinical information among students, residents, and other medical professionals. Formerly known as Practical Guide to the Care of the Medical Patient, this volume continues to provide a fast, effective, and efficient way to identify the important clinical, laboratory, and diagnostic imaging information you need to get through your internal medicine clerkship or residency. - Consult this title on your favorite device, conduct rapid searches, and adjust font sizes for optimal readability. - Benefit from the expert guidance of Dr. Fred Ferri, a leading teacher, clinician, and author. - Confidently manage patients with the latest clinical information, drug therapies, and lab tests. - Apply the latest knowledge and techniques with this updated and streamlined title, which still stays true to the Ferri name. - Quickly find important information with content organized into three major sections: Section I, titled "Surviving the Wards," contains information on charting, laboratory evaluation and formulary; Section II provides the differential diagnosis of common signs and symptoms likely to be encountered in the acute care setting; Section III has been completely revised and subdivided into 11 specialty specific diseases and disorders. - Carry just the sections you need, add personalized materials, and keep everything together and safe with an improved ring binder and design. - Access the full text and procedural videos online at Expert Consult.
Our understanding of multiple myeloma (MM) is growing at a formidable pace, particularly in terms of risk factors and potential drug targets. Minimal residual disease (MRD) negativity is set to become the new benchmark in treatment, and cytogenetic analysis is now paving the way for personalized therapies. This second edition of 'Fast Facts: Multiple Myeloma and Plasma Cell Dyscrasias' includes: - the new IMWG SLiM CRAB criteria - the latest advances in diagnostic tests and imaging - cytogenetics and genetic profiling - induction therapy prior to SCT - new lenalidomide- and bortezomib-based regimens - second-generation proteasome inhibitors, histone deacetylase inhibitors and monoclonal antibodies treatments. This Fast Facts handbook provides a comprehensive overview of MM and other plasma cell dyscrasias, from bench to bedside, presenting the pathogenesis, diagnosis and treatment in the context of daily clinical practice. Contents: • Epidemiology and etiology Predisposing conditions associated with MM • Pathophysiology of MM and MGUS • Diagnosis, staging and monitoring of multiple myeloma • Genetics and multiple myeloma • Treatment of newly diagnosed multiple myeloma • Stem cell transplantation in multiple myeloma • Relapsed and refractory multiple myeloma • Bone disease and renal complications • AL amyloidosis • Rare plasma cell dyscrasias • Supportive care
Abnormalities of thyroid function rival diabetes mellitus in terms of prevalence and can affect any system in the body. In the UK and North America it is estimated that palpable thyroid nodules are present in 1 in 20 of the population, and in the UK alone 20,000 tests are carried out each year in clinical chemistry laboratories. Thus, all doctors can expect to encounter thyroid disease in one form or another. Thyroid disorders are generally very responsive to treatment, but there are traps for the unwary - not least because of the frequent atypical presentations and the widespread prevalence of subclinical disease. 'Fast Facts: Thyroid Disorders' is written by two leading experts of international standing who share a wealth of clinical and research experience. The text, which is comprehensively illustrated to make core clinical information easily accessible, is a concise and practical guide for all who manage patients with these common conditions. • A concise guide to the recognition of thyroid disorders and the selection of appropriate thyroid function tests • Provides expert advice on when to test, when to treat and when to refer, ensuring rapid initiation of appropriate therapy • Highlights the particular challenges posed by thyroid disease during pregnancy • Covers the management of thyroid eye conditions • Sound, dependable advice for the healthcare team and patient in coping with these common conditions Contents: • Glossary • Introduction • Thyroid physiology and function tests • Hyperthyroidism: etiology and presentation • Hyperthyroidism: diagnosis and management • Hypothyroidism: etiology and presentation • Hypothyroidism: diagnosis and management • Pregnancy and the thyroid • Thyroid nodules and thyroid cancer
'Fast Facts: Marginal Zone Lymphoma' provides an overview of MZL for healthcare professionals and others with an interest in this blood cancer. It summarizes what is known about the pathophysiology of the disease, and discusses the importance of accurate diagnosis, staging, and prognosis, together with existing approaches to treatment and monitoring, including the latest evidence for new therapies in the R/R setting. With an eye to the future, it also reviews some of the therapies in development, which may ultimately improve quality of life and ensure better outcomes for patients with MZL.
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues is a Revised Fourth Edition of the WHO series on histological and genetic typing of human tumours. This authoritative, concise reference provides an international standard for oncologists and pathologists and will serve as an indispensable guide for use in the design of studies monitoring response to therapy and clinical outcome. Diagnostic criteria, pathological features, and associated genetic alterations are described in a strictly disease-oriented manner. Sections on all recognized neoplasms and their variants further include new ICD-O codes, epidemiology, clinical features, macroscopy, prognosis, and predictive factors. This classification, prepared by 132 authors from 23 countries, contains about 1300 color images and tables and more than 4500 references.
This volume is the first of its kind to emphasize the visual approach in the diagnosis of cutaneous lymphoid infiltrates. Written and designed in an accessible yet highly detailed format by an expert in the field, this book bridges the knowledge gaps so often found when dealing with skin lymphomas. Complete with more than two hundred high quality images and illustrations, Diagnosis of Cutaneous Lymphoid Infiltrates offers pearls and pitfalls as well as differential diagnoses. Additionally, images are explained and decoded with the use of illustrations and analogies, proving to be an invaluable resource for pathologists, dermatologists, dermatopathologists, hematopathologists, and residents and fellows in these fields.
